文献速递胸部CT

利用多期CT影像组学特征预测肺腺癌患者EGFR突变状态

Using Multi-phase CT Radiomics Features to Predict EGFR Mutation Status in Lung Adenocarcinoma Patients.
PubMed 文献 · Acad Radiol · 2024-01-30

本研究从两家医院纳入424例肺腺癌患者,基于术前平扫CT、动脉期CT和静脉期CT提取影像组学特征,构建临床模型、8个影像组学模型及临床-影像组学模型。多期CT影像组学模型在外部验证队列的AUC为0.925(95%CI 0.879-0.971),高于平扫、动脉期、静脉期及临床模型(AUC分别为0.860、0.792、0.753、0.706,均P<0.05);临床-影像组学模型AUC为0.927(95%CI 0.882-0.971),与多期CT影像组学模型相当(P>0.05)。

要点

  • 多期CT影像组学模型在外部验证队列预测EGFR突变AUC为0.925(95%CI 0.879-0.971),高于平扫、动脉期、静脉期及临床模型(均P<0.05)。
  • 临床-影像组学模型验证队列AUC为0.927(95%CI 0.882-0.971),与多期CT影像组学模型性能相当(P>0.05)。
  • 多期CT影像组学模型可能辅助肺腺癌患者的个体化治疗决策。

核心结论

  • 多期CT影像组学模型在识别肺腺癌患者EGFR突变状态方面表现良好,可能辅助个体化治疗决策。

研究设计与样本

  • 从两家医院纳入424例肺腺癌患者,按医院分为训练队列297例和外部验证队列127例,均行术前平扫CT、动脉期CT和静脉期CT检查。

诊断标准与关键数值

  • 多期CT影像组学模型验证队列AUC为0.925(95%CI 0.879-0.971),高于平扫CT模型AUC 0.860(95%CI 0.794-0.927)、动脉期CT模型AUC 0.792(95%CI 0.713-0.871)、静脉期CT模型AUC 0.753(95%CI 0.669-0.838)及临床模型AUC 0.706(95%CI 0.620-0.791)(均P<0.05)。
  • 临床-影像组学模型验证队列AUC为0.927(95%CI 0.882-0.971),与多期CT影像组学模型性能相当(P>0.05)。

临床应用与阅片要点

  • 作者认为多期CT影像组学模型可能辅助肺腺癌患者的个体化治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: This study aimed to non-invasively predict epidermal growth factor receptor (EGFR) mutation status in patients with lung adenocarcinoma using multi-phase computed tomography (CT) radiomics features.

MATERIALS AND METHODS: A total of 424 patients with lung adenocarcinoma were recruited from two hospitals who underwent preoperative non-enhanced CT (NE-CT) and enhanced CT (including arterial phase CT [AP-CT], and venous phase CT [VP-CT]). Patients were divided into training (n = 297) and external validation (n = 127) cohorts according to hospital. Radiomics features were extracted from the NE-CT, AP-CT, and VP-CT images, respectively. The Wilcoxon test, correlation analysis, and simulated annealing were used for feature screening. A clinical model and eight radiomics models were established. Furthermore, a clinical-radiomics model was constructed by incorporating multi-phase CT features and clinical risk factors. Receiver operating characteristic curves were used to evaluate the predictive performance of the models.

RESULTS: The predictive performance of multi-phase CT radiomics model (AUC of 0.925 [95% CI, 0.879-0.971] in the validation cohort) was higher than that of NE-CT, AP-CT, VP-CT, and clinical models (AUCs of 0.860 [95% CI,0.794-0.927], 0.792 [95% CI, 0.713-0.871], 0.753 [95% CI, 0.669-0.838], and 0.706 [95% CI, 0.620-0.791] in the validation cohort, respectively) (all P < 0.05). The predictive performance of the clinical-radiomics model (AUC of 0.927 [95% CI, 0.882-0.971] in the validation cohort) was comparable to that of multi-phase CT radiomics model (P > 0.05).

CONCLUSION: Our multi-phase CT radiomics model showed good performance in identifying the EGFR mutation status in patients with lung adenocarcinoma, which may assist personalized treatment decisions.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang G, Man Q, Shang L, et al. Using Multi-phase CT Radiomics Features to Predict EGFR Mutation Status in Lung Adenocarcinoma Patients. Acad Radiol. 2024. PMID: 38290884. doi:10.1016/j.acra.2023.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。